Skip to main content
SpringerLink
Log in

Genomic strategy not cost effective for ovarian cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

Reference

  • Wallbillich JJ, et al. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. Gynecologic Oncology : 19 Apr 2016. Available from: URL: http://doi.org/10.1016/j.ygyno.2016.04.024

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genomic strategy not cost effective for ovarian cancer. PharmacoEcon Outcomes News 753, 17 (2016). https://doi.org/10.1007/s40274-016-3050-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3050-0

Search

Navigation